Logo
x

Search category

Subscribe Now

Everest Medicines

Everest Medicines Signed a MoU with Shanghai Pharma Subsidiary to Advance the Commercialization of Xerava (eravacycline) in Mainland China

Everest Medicines Signed a MoU with Shanghai Pharma Subsidiary to Advance the Commercialization of Xerava (eravacycline) in Mainla...

  • April 19, 2023
Singapore HSA Accepts NDA of Everest Medicines’ Nefecon for the Treatment of Primary IgA Nephropathy

Singapore HSA Accepts NDA of Everest Medicines’ Nefecon for the Treatment of Primary IgA Nephropathy

  • April 6, 2023
Everest Medicines’ Xerava (eravacycline) Receives NMPA’s Approval for Complicated Intra-Abdominal Infections in Adult Patients

Everest Medicines’ Xerava (eravacycline) Receives NMPA’s Approval for Complicated Intra-Abdominal Infections in Adult Patients

  • March 17, 2023
Everest Medicines and Calliditas Receives Priority Review for Nefecon in IgA Nephropathy for China

Everest Medicines and Calliditas Receives Priority Review for Nefecon in IgA Nephropathy for China

  • January 2, 2023
Everest Medicines Licensing Partner Pfizer Reports the US FDA and EMA’s Acceptance of NDA and MAA for Etrasimod in Ulcerative Colitis

Everest Medicines Licensing Partner Pfizer Reports the US FDA and EMA’s Acceptance of NDA and MAA for Etrasimod in Ulcerative Coli...

  • December 22, 2022
Everest Medicines Receives the NMPA’s IND Approval for EVER001 to Treat Renal Diseases

Everest Medicines Receives the NMPA’s IND Approval for EVER001 to Treat Renal Diseases

  • September 26, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.